Rosacea Awareness Month brings focus to five developments in rosacea

April has been designated Rosacea Awareness Month by organizations including the National Rosacea Society and the Acne and Rosacea Society of Canada.

Developments reported on Healio.com/Dermatology include research presented at this year’s American Academy of Dermatology Annual meeting that microneedling with tranexamic acid solution was an effective treatment for rosacea and study results finding that rosacea may be tied to increased risk for inflammatory bowel disease:

Microneedling with tranexamic acid solution effectively treated rosacea

ORLANDO, Fla. — Microneedling with tranexamic acid solution was an effective treatment for women with erythematotelangiectatic rosacea, according to late-breaking research presented at the American Academy of Dermatology Annual Meeting.

Fotini Bageorgou, MD, reported on a study of 20 women, aged between 27 and 65 years, with erythematotelangiectatic rosacea. Read more

Rosacea may be tied to increased risk for inflammatory bowel disease

There was an increased risk for inflammatory bowel disease in patients with rosacea, according to study results published in the Journal of the American Academy of Dermatology.

Researchers in Taiwan used the Taiwanese National Health Insurance Research Database to identify 89,356 patients with rosacea and 178,712 matched patients without rosacea (reference cohort) between 1997 and 2013 for analysis. Read more

Radiofrequency effectively treats rosacea when compared with pulsed dye laser

Radiofrequency therapy was as effective as pulsed dye laser in treating rosacea, particularly in patients with papulopustular rosacea, according to published study results.

Researchers studied 30 patients with rosacea (19 women; average age, 43.4 years), including 20 patients with erythematotelangiectatic rosacea (ETR) and 10 patients with papulopustular rosacea (PPR). Read more

Women with rosacea at higher risk for migraine

Women with rosacea had a significantly higher risk for incident migraine compared with the general Danish population, according to study results recently published in the Journal of the American Academy of Dermatology.

Alexander Egeberg , MD, PhD, of the department of dermatology and allergy, Herlev and Gentofte Hospital, University of Copenhagen, Denmark, and colleagues used nationwide registers of all Danish citizens aged 18 years or older to study the prevalence of and risk for new-onset migraine in patients with rosacea. Read more

VIDEO: Soolantra vs. metronidazole in relapse of rosacea

WASHINGTON — In a video perspective on the eve of the American Academy of Dermatology Annual Meeting 2016, Hillary Baldwin, MD, discusses a two-part study comparing Soolantra (ivermectin, Galderma) cream 1% with metronidazole 0.75% cream in treating patients with papulopustular rosacea.

Baldwin, director of the Acne Research and Treatment Center in Morristown, New Jersey, discussed the second part of the study, which looked at relapse rates in patients over 1 year. Watch Video